No resume content available
POLIVY® (polatuzumab vedotin-piiq) Approved for 1L DLBCL, NOS or HGBL and IPI ≥ 2
Learn about POLIVY® (polatuzumab vedotin-piiq) in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with certain types of previously untreated diffuse large B-cell lymphoma (DLBCL). See full safety information.
5 languages with 5 regional variants
